BioSpace News Archive

Centene Corporation (NYSE: CNC) announced today it will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference, to be held January 11-14, 2021 . Centene will participate in a virtual format on Monday, January 11 th at 9:10 a.m. Eastern Standard Time (EST). A simultaneous live audio webcast is available at: ht

StageZero Life Sciences, Ltd. announced that it has engaged Toronto based McGovern Hurley LLP as its auditors.

Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced that Dr. Ray Tabibiazar will be stepping down from the Aravive Board of Directors but will remain an advisor to the company, effective December 31, 2020.

Medical peristaltic pump represents a type of positive displacement pump popularly used for transporting various types of fluids.

Preeclampsia is a hypertensive disorder of pregnancy and affects about 5% of pregnant women globally, out of whom 0.5% to 1% develop it in the severe form.

Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours

A peer-reviewed updated summary of COVID-19 early-treatment best practices was published Wednesday morning, in Reviews in Cardiovascular Medicine, an interdisciplinary scientific, open access journal.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). “We are pleased to commence dosing in our second proof-of-concept study of LX9211,” said Praveen Tyle, Ph.D.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. John Fahy, MD, MSc, as a Scientific and Clinical advisor to the Company to assist in the expansion and the analysis of the clinical data on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3

Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz® in treatment of a model of heart attack.